Moberg Pharma AB

Terclara® was launched in Norway in collaboration with our partner Allderma. “We are proud to announce that the Norwegian success follows the highly successful Swedish launch and is built on the same proven model: a combination of broad distribution via all pharmacy chains, targeted marketing and close collaboration with heath care professionals and the pharmacy sector.” says Mimmi Frölén, CEO of Allderma. As consumer sell-out data is not reported in Norway, the market leadership is based on sell-in data to pharmacies. Terclara® recorded the highest sell-in within its segment both in May (market share: 48% by value, 45% by units) and April (38% by value, 35% by units). As in Sweden last year, the launch in Norway was timed ahead of peak season, with pharmacy deliveries beginning in February and consumer marketing starting at the end of March 2025. Despite the short time since launch, Terclara® has already achieved market leadership for the full period January–May 2025, with a market share of 32% by value and 29% by units.[1] "We are very pleased to have already achieved our goal of becoming the market leader also in Norway," says Anna Ljung, CEO of Moberg Pharma. "This is clear evidence that our launch strategy is working and that demand for effective topical treatments is strong across multiple markets." For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se About this information The information was submitted for publication, through the agency of the contact person set out above, on June 16th, 2025, at 8.00 am CEST. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB). About Allderma Pharmaceuticals, www.allderma.se Allderma Pharmaceuticals is a Swedish pharmaceutical company that since 2001 develops, sells and markets over the counter and self-care products. The range spans a number of different treatment areas, with a focus and expertise in dermatology. Founder Hans Svartholm started Allderma after working in the pharmaceutical industry for many years. The idea was simple and still applies it should be easy to find an effective and safe product for the most common skin problems. Allderma emphasis and invests in information for healthcare providers, pharmacists, doctors and consumers. Product specialists work continuously to be a spear head in research and innovation within dermatology. Allderma has been part of 3iM Invest AB's investment area Consumer Healthcare since 2020. [1] Source: IQVIA MIDAS, Pharmacy Sell-In data, Jan-May 2025

The annual general meeting of Moberg Pharma AB (publ) on 22 May 2025 resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme LTI 2025 resolved by the annual general meeting and for the purpose of covering certain costs, primarily social security costs, that may arise as a result of incentive programs – to authorize the board of directors to resolve on a directed share issue of redeemable- and convertible class C shares. The general meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorization may be made on one or several occasions until the next annual general meeting and at a price not less than 100 per cent and no more than 105 per cent of the quotient value of the share of approximately SEK 1. The board of directors resolved to exercise the share issue authorization for the said purpose to issue 832,213 class C shares to Vator Securities AB. The share issues shall be made at a price corresponding to the quotient value of the share and must be subscribed for within three weeks from the day of the resolution on the new issue. The board of directors has the right to extend the subscription period. The board of directors has resolved to exercise the repurchase authorization for the said purpose by repurchasing all issued class C shares against payment corresponding to 100 per cent of the quota value of the share, corresponding to approximately SEK 1 per share. Repurchase of the class C shares may be effected no later than on August 31st 2025. The class C shares will, following the repurchase, be converted to common shares to secure the delivery under the incentive programme. The company currently holds 879,227 own common shares. After repurchase and conversion of C-shares in accordance with the above, the number of own common shares held will amount to 1,711,440. For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: mark.beveridge@moberpharma.se About this information The information was submitted for publication at 1:30 pm CEST on June 3rd 2025 through the contact persons above. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).

For additional information, please contact: Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: anna.ljung@mobergpharma.se Mark Beveridge, VP Finance, Phone: +46 76 805 82 88, e-mail: mark.beveridge@mobergpharma.se About this information The information was submitted for publication, through the agency of the contact person set out above, on April 11, 2025, at 8.00 am CET. About Moberg Pharma, www.mobergpharma.com Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).